Boston Scientific Corporation Officer Changes

On October 7, 2026, Boston Scientific Corporation announced significant changes in its executive leadership. Joe Fitzgerald has been promoted to Executive Vice President and Chief Operating Officer, effective January 1, 2027. He will oversee global operations, business units, and regions. In conjunction with this appointment, the company will establish three new reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg, also effective January 1, 2027. These changes are intended to increase efficiency, enable faster decision-making, and support strategic investment allocation. Additionally, Emily Woodworth will transition from her role as Chief Accounting Officer on March 1, 2027, and Mark Bickel will be appointed as her successor. Fitzgerald's compensation package includes a base salary of $1,050,000, eligibility for annual bonuses and equity awards, and continued participation in executive benefit plans. The new structure aims to support the company's continued growth and evolving portfolio.